Cargando…
Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
AIMS: To investigate the correlations between renal biomarkers and the treatment outcomes of ranibizumab for diabetic macular edema (DME). METHODS: This hospital-based study retrospectively enrolled 88 eyes from 67 patients who had received one-year intravitreal ranibizumab treatment for DME. Best-c...
Autores principales: | Lai, Ivan Pochou, Huang, Wei-Lun, Yang, Chung-May, Yang, Chang-Hao, Ho, Tzyy-Chang, Hsieh, Yi-Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450296/ https://www.ncbi.nlm.nih.gov/pubmed/32908935 http://dx.doi.org/10.1155/2020/7239570 |
Ejemplares similares
-
Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study
por: Fang, Yi-Chung, et al.
Publicado: (2023) -
Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022) -
Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema
por: Wang, Jia-Kang, et al.
Publicado: (2021) -
Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study
por: Lai, Tso-Ting, et al.
Publicado: (2019) -
Combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections for patients with diabetic macular edema refractory to intravitreal ranibizumab monotherapy
por: Chiu, Chiung-Yi, et al.
Publicado: (2021)